Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

[1]  M. Rezai,et al.  Translating the concept of intrinsic subtypes into an oncoplastic cohort of more than 1000 patients - predictors of recurrence and survival. , 2015, Breast.

[2]  J. Reis-Filho,et al.  Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. , 2015, Journal of the National Cancer Institute.

[3]  N. Bundred,et al.  Molecular phenotypes of DCIS predict overall and invasive recurrence. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Rezai,et al.  Abstract P1-16-07: Translating the concept of intrinsic subtypes into an oncoplastic cohort of more than 1000 patients-predictors of recurrence and survival , 2015 .

[5]  C. Perou,et al.  CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping , 2015, Clinical Cancer Research.

[6]  A. Luini,et al.  Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Tot.  Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival , 2015, Annals of surgical oncology.

[8]  Huang Jun,et al.  Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype , 2014 .

[9]  F. Su,et al.  HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy , 2014, World Journal of Surgical Oncology.

[10]  J. Griggs,et al.  Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Coebergh,et al.  Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. , 2014, Breast.

[12]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Sørlie,et al.  Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study , 2013, BMC Cancer.

[14]  E. Sigmund,et al.  Ductal carcinoma in situ of the breasts: review of MR imaging features. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  H. Bartelink,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  B. Bonanni,et al.  Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype , 2013, British Journal of Cancer.

[18]  S. Kurbel.  In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer , 2013, Tumor Biology.

[19]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Leonardi,et al.  Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study , 2012, Radiation oncology.

[21]  E. Rakovitch,et al.  Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[22]  E. Rakovitch,et al.  HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ , 2012, British Journal of Cancer.

[23]  F. Bertucci,et al.  A refined molecular taxonomy of breast cancer , 2011, Oncogene.

[24]  X. Shu,et al.  Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study , 2011, BMC Cancer.

[25]  S. Duffy,et al.  Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease , 2010, British Journal of Cancer.

[26]  Mika Watanabe,et al.  Radiologic-pathologic correlation of ductal carcinoma in situ. , 2010, Radiographics : a review publication of the Radiological Society of North America, Inc.

[27]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Parise,et al.  Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999–2004 , 2009, The breast journal.

[29]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[30]  J. Coebergh,et al.  Screening caused rising incidence rates of ductal carcinoma in situ of the breast , 2009, Breast Cancer Research and Treatment.

[31]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Colditz,et al.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.

[33]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Coebergh,et al.  On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands , 2008, Cancer Causes & Control.

[35]  M. J. van de Vijver,et al.  Immunohistochemical categorisation of ductal carcinoma in situ of the breast , 2007, British Journal of Cancer.

[36]  L. Kiemeney,et al.  Uncommon breast tumors in perspective: Incidence, treatment and survival in the Netherlands , 2007, International journal of cancer.

[37]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[38]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[39]  P. Bourne,et al.  Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. , 2007, Annals of clinical and laboratory science.

[40]  Sehwan Han,et al.  HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry , 2006, Histopathology.

[41]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[43]  R. J. Rosser.  Consensus conference on the classification of ductal carcinoma in Situ , 1998, Cancer.

[44]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[45]  S J Schnitt,et al.  The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy. , 1991, Annals of surgery.

[46]  T. Tot,et al.  Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival , 2015, Annals of Surgical Oncology.